| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_067c1f6ec07067ca0b49b39431dd1631 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18534
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
1994-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1998-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afa3e3f6ab1b8f65f7f7c227a2491f23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1594de485127a3ec74e525530c1020eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85cdb3a83ccfd9233090442dc5a7a47b |
| publicationDate |
1998-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0714306-B1 |
| titleOfInvention |
Inactivated respiratory syncytial viral vaccines |
| abstract |
An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using beta-propiolactone, a non-ionic detergent, particularly n-octyl-alpha-D-glucopyranoside and n-octyl-beta-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications. |
| priorityDate |
1993-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |